

prevention of osteoporosis in reproductive age women and for the prevention and treatment of osteoporosis, alone or either in association with hormone replacement therapy or calcium and vitamin D in post-menopausal and elderly women, by administering to a patient a therapeutically effective amount of said pharmaceutical composition.

19. (Withdrawn) The use of a pharmaceutical composition of claim 10, in the treatment of inflammatory conditions caused by excessive nitric oxide and/or immunoglobulin E production such as: atopic dermatitis, rheumatoid and osteo-arthritis, neurodegenerative diseases (such as Alzheimer, multiple sclerosis, amyotrophic lateral sclerosis), diabetes, by administering to a patient a therapeutically effective amount of said pharmaceutical composition.

20. (Withdrawn) The use of a pharmaceutical composition of claim 10 for reduction of fever associated with bacterial, viral, or allergic illnesses, by administering to a patient a therapeutically effective amount of said pharmaceutical composition.

21. (Withdrawn) The use of a pharmaceutical composition of claim 10 for the treatment of obstetrical and gynecologic conditions such as endometriosis, fibroids (leiomyoma), pre-eclampsia and recurrent abortion in a patient by administering to a patient a therapeutically effective amount of said pharmaceutical composition.

22. (Withdrawn) Use of the stilbene derivatives according to claim 10, as food additive by adding an effective amount of the stilbene derivative to a food selected from a powdered or liquid formula, cereal, and in canned food to prevent the toxic effects of environmental exposure to AhR ligands.

23. (Withdrawn) Use of the stilbene derivatives according to claim 10, for impregnating a cigarette filter, by adding an effective amount of the stilbene derivative to said cigarette filter.

24. (Withdrawn) The use of a pharmaceutical composition of claim 10, for the treatment of condition selected from the group consisting of dermatitis, acne, psoriasis, hyperkeratotic lesions, eczema, skin aging and wrinkling associated with common environmental exposure to


AhR ligands cold or flu symptoms related to viral infections aggravated by AhR ligands, AhR ligand-induced triggering of HIV (and other viruses) gene expression and progression of AIDS, prion-induced Spongiformis Encephalitis, osteoporosis, alone or either in association with hormone replacement therapy or calcium and vitamin D in post-menopausal women, inflammatory conditions caused by excessive nitric oxide, rheumatoid and osteo-arthritis, neurodegenerative diseases, diabetes, fever associated with bacterial, viral, or allergic illnesses, endometriosis, fibroids (leiomyoma), pre-eclampsia and recurrent abortion by administering to a patient in need of such treatment a therapeutically effective amount of said pharmaceutical composition.

25. (Withdrawn) The use of a pharmaceutical composition of claim 8, for the treatment of condition selected from the group consisting of dermatitis, acne, psoriasis, hyperkeratotic lesions, eczema, skin aging and wrinkling associated with common environmental exposure to AhR ligands cold or flu symptoms related to viral infections aggravated by AhR ligands, AhR ligand-induced triggering of HIV (and other viruses) gene expression and progression of AIDS, prion-induced Spongiformis Encephalitis, osteoporosis, alone or either in association with hormone replacement therapy or calcium and vitamin D in post-menopausal women, inflammatory conditions caused by excessive nitric oxide, rheumatoid and osteo-arthritis, neurodegenerative diseases, diabetes, fever associated with bacterial, viral, or allergic illnesses, endometriosis, fibroids (leiomyoma), pre-eclampsia and recurrent abortion by administering to a patient in need of such treatment a therapeutically effective amount of said pharmaceutical composition.

26. (Previously Presented) The pharmaceutical compositions of claim 13, comprising 20 to 200 mg per dosage unit.

27. (Previously Presented) The pharmaceutical compositions of claim 13, comprising 10 to 100 mg per dosage unit.

28. (Currently Amended) A compound having formula I:



wherein the compound is a trans isomer and

R3, R5 are selected from the group consisting of OH, O-C₁-C₆ alkoxy, F, [[Cl]] Cl, and CF₃;
R4, R5' are H;

R3', R4' are independently selected from the group consisting of OH, O-C₁-C₆ alkoxy, F, Cl, CF₃, and H;

with the following provisos:

R3' is different than R4';

wherein R3 and R5 are both OH, OCH₃, or OCH₃CH₃, R4' is not OH, OCH₃, or OCH₃CH₃;

wherein R3 and R5 are both Cl, R4' is not Cl;

wherein R3 and R5 are both Cl, R3' is not OH or OCH₃ ;

and wherein R3 and R5 are both F, R3' is not OCH₃;


and symmetrical derivatives thereof.

29. (Previously Presented) The stilbene derivatives of claim 28, wherein R3 and R5 are Cl.

30. (Previously Presented) The stilbene derivatives of claim 28, wherein R3' is H and R4' is Cl or OCH₃.

31. (Previously Presented) Stilbene derivatives selected in the group comprising (E)-1-(4'-trifluoromethylphenyl)-2-(3,5-ditrifluoromethylphenyl)-ethene, (E)-1-(4'-methoxyphenyl)-2-(3,5-dichlorophenyl)-ethene, and (E)-1-(4'-chlorophenyl)-2-(3,5-dichlorophenyl)-ethene.

32. (Currently Amended) A pharmaceutical composition comprising an effective amount of at least one compound having formula I:



wherein the compound is a cis or trans isomer and

R3, R5 are selected from the group consisting of OH, O-C₁-C₆ alkoxy, F, Cl, and CF₃;

R4, R5' are H;

R3', R4' are independently selected from the group consisting of OH, O-C₁-C₆ alkoxy, F, Cl, CF₃, and H;

with the following provisos:

wherein R3 and R5 are both OH, OCH₃, or OCH₃CH₃, R4' is not OH, OCH₃, or OCH₃CH₃;

wherein R3 and R5 are both Cl, R3' is not OH or OCH₃;

and symmetrical derivatives thereof;

and a pharmaceutically acceptable carrier.